Mertz P, Hentgen V, Boursier G, Delon J, Georgin-Lavialle S
Sorbonne University, Department of Internal Medicine, DMU3ID, ERN RITA, Hôpital Tenon, University, Assistance publique-hôpitaux de Paris (AP-HP), 4 rue de la Chine, 75020 Paris, France; Centre de référence des maladies autoinflammatoires et de l'amylose (CEREMAIA); service de pédiatrie, Centre hospitalier de Versailles, 78150 le Chesnay, France; Université Paris Cité, Institut Cochin, Inserm, CNRS, 75014 Paris, France.
Centre de référence des maladies autoinflammatoires et de l'amylose (CEREMAIA); service de pédiatrie, Centre hospitalier de Versailles, 78150 le Chesnay, France.
Autoimmun Rev. 2025 Jan 31;24(2):103715. doi: 10.1016/j.autrev.2024.103715. Epub 2024 Dec 5.
Autoinflammatory diseases (AID) are conditions leading to a hyperactivation of innate immunity without any underlying infection, and may be poly- (e.g. Still's disease) or monogenic. The number of monogenic AID is continuously expanding, with the discovery of novel pathologies and pathophysiological mechanisms, facilitated in part by easier access to pangenomic sequencing. Actinopathies with autoinflammatory manifestations represent a newly emerging subgroup of AID, associated with defects in the regulation of actin cytoskeleton dynamics. These diseases typically manifest in the neonatal period and variably combine a primary immunodeficiency of varying severity, cytopenia (particularly thrombocytopenia), autoinflammatory manifestations primarily affecting the skin and digestive system, as well as atopic and autoimmune features. Diagnosis should be considered primarily when encountering an early-onset autoinflammatory skin and digestive disorder, along with a primary immunodeficiency and either thrombocytopenia or a bleeding tendency. Some of these diseases exhibit specific features, such as a risk of macrophage activation syndrome (MAS) or a predisposition to atopy or lymphoproliferation. The complete pathophysiology of these diseases is not yet fully understood, and further studies are required to elucidate the underlying mechanisms, which could guide therapeutic choices. In most cases, the severity of the conditions necessitates allogeneic marrow transplantation as a treatment option. In this review, we discuss these novel diseases, providing a practical approach based on the main associated biological abnormalities and specific clinical characteristics, with a special focus on the newly described actinopathies DOCK11 and ARPC5 deficiency. Nonetheless, genetic testing remains essential for definitive diagnosis, and various differential diagnoses must be considered.
自身炎症性疾病(AID)是指在无任何潜在感染的情况下导致先天性免疫过度激活的病症,可呈多基因性(如斯蒂尔病)或单基因性。随着新的病理学和病理生理机制的发现,单基因AID的数量在不断增加,这在一定程度上得益于全基因组测序的更容易获取。具有自身炎症表现的肌动蛋白病代表了AID的一个新出现的亚组,与肌动蛋白细胞骨架动力学调节缺陷有关。这些疾病通常在新生儿期表现出来,并不同程度地合并有不同严重程度的原发性免疫缺陷、血细胞减少(尤其是血小板减少)、主要影响皮肤和消化系统的自身炎症表现,以及特应性和自身免疫特征。当遇到早发性自身炎症性皮肤和消化系统疾病,同时伴有原发性免疫缺陷和血小板减少或出血倾向时,应首先考虑诊断。其中一些疾病表现出特定特征,如巨噬细胞活化综合征(MAS)风险或特应性或淋巴增殖倾向。这些疾病的完整病理生理学尚未完全了解,需要进一步研究以阐明潜在机制,这可能会指导治疗选择。在大多数情况下,病情的严重程度使得异基因骨髓移植成为一种治疗选择。在本综述中,我们讨论这些新出现的疾病,基于主要相关生物学异常和特定临床特征提供一种实用方法,特别关注新描述的肌动蛋白病DOCK11和ARPC5缺乏症。尽管如此,基因检测对于明确诊断仍然至关重要,并且必须考虑各种鉴别诊断。